CD274 and gastric cancer: The CheckMate-649 study demonstrated that nivolumab combined with chemotherapy significantly extended overall survival (OS) in untreated advanced GC patients, particularly those with PD-L1 CPS ≥ 5, compared to chemotherapy alone.